BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

Starbucks Is Earning More Per Customer Than It Has in Years. The Stock Is Priced as If That’s Just the Beginning.

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 17, 2026
in Expectations Audits
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

In one breath

The filed numbers show a business climbing out of a genuine hole: four straight quarters of comparable-sales growth, margins expanding, and customers returning to stores. The stock, trading near its 52-week high at a price-to-earnings multiple more than twice its own decade median, is priced as if that recovery is only the first chapter of a much longer story. Whether the story has that many chapters left is the question the filings cannot yet answer.

The hole was real

Two years ago, Starbucks was in genuine trouble. The quarter ended June 2024 brought a meaningful drop in global comparable store sales, the kind of number that tells you customers are choosing somewhere else. Elliott Management and Starboard Value both disclosed stakes that summer, the financial equivalent of a knock on the boardroom door. By September 2024, Laxman Narasimhan was out and Brian Niccol, the executive who had rebuilt Chipotle’s reputation, was in.

Niccol called his plan “Back to Starbucks,” a name that acknowledged, without quite saying so, that the company had drifted from whatever made it work. He renovated more than a thousand North American stores, restructured corporate layers, and told investors the business needed to earn its customers back one visit at a time. The market, as markets do, started pricing in the happy ending before the chapters were written.

What the filings actually show

The most recent evidence is genuinely good. The 10-Q for the quarter ended June 28, 2026 shows revenue down slightly from the same quarter a year earlier, but the comparable-store sales figure, which strips out the effect of new and closed locations, rose nearly 8% globally. That distinction matters: closing hundreds of underperforming locations in 2026 while opening more new ones shrinks reported revenue even as the underlying business strengthens. More customers came in more often, and they spent a little more each visit.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Starbucks and 500+ other names, on the same official data.See the evidence engine →

Pull back to the full fiscal year 2025, filed in the 10-K for the year ended September 28, 2025, and the picture is more complicated. Revenue grew modestly from the prior year, but net income fell by roughly half on roughly the same sales. The net margin, what’s left of each dollar of revenue after every bill is paid, dropped to around 5%, compared to about double that the year before. That compression reflects the real cost of the turnaround: labor investment, store renovations, and restructuring charges don’t come free.

The Q3 2026 earnings call, transcribed by The Motley Fool on August 7, 2026, showed management raising its full-year adjusted earnings-per-share guidance meaningfully above the prior range. The non-GAAP operating margin, a measure that excludes restructuring and other one-time items, expanded by more than four percentage points year-over-year for the quarter. That’s a meaningful move in a single quarter, and it’s what has the market excited.

The price tag on the comeback

Here is where the math and the mood pull apart. “The math” is what the filed fundamentals justify on their own terms. “The mood” is what the market is currently willing to pay. Right now, those two readings are far apart.

Our data puts the trailing price-to-earnings multiple, the price tag per dollar of profit the company has already earned, at 65.5, against a decade median of 27.3. The stock is sitting at the 100th percentile of its own valuation history, meaning it has never, in the past ten years of our data, traded at a higher earnings multiple than it does today. A multiple that high on a business earning at a thin net margin means the market is paying for a very different Starbucks than the one in the most recent annual filing.

To put that in graspable terms: a business that earns a nickel of profit on every dollar of sales is priced as if each of those nickels is extraordinarily precious. A household analogy, kept in the third person as our methodology requires: imagine a small bakery that clears $10,000 a year in profit, and someone offers to buy it for $650,000. That buyer is not paying for today’s bakery. They are paying for the bakery they believe it will become.

BullScope TerminalYou just read Starbucks’ filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The Washington Times reported on July 29, 2026 that Starbucks raised its annual outlook following the strong quarter. Several major analysts raised their price targets in response, according to Public.com’s analyst tracker. The optimistic case is coherent: if the margin recovery continues and comparable-sales growth holds at recent rates, the earnings base grows fast enough to justify a high multiple. The question is how many things have to go right simultaneously.

The friction in the story

Niccol told reporters on August 16, 2026, as reported by Renascence, that the company is focused on retaining “financially stretched customers” through service rather than discounting. That phrase is worth sitting with. A premium latte is a discretionary purchase, the kind a household cuts first when budgets tighten. The recent traffic recovery is real, but it arrived during a period of easing inflation and before any significant macro deterioration. Whether it holds if conditions shift is a question the filed numbers cannot answer yet.

Labor is the other open variable. Labor Notes reported in April 2026 that union baristas accused the company of “regressive bargaining,” reopening previously settled contract issues. Starbucks employs hundreds of thousands of people, and labor is its largest cost line. A contract that costs more than the market expects would compress the very margins the stock is pricing in.

The Simply Wall St analysis published after Q3 results framed the core tension plainly: several valuation approaches suggest the stock is pricing in meaningfully more value than current fundamentals support, depending on the assumptions used. The width of that range is itself informative. It reflects genuine uncertainty about how durable the recovery is, not a clean answer in either direction.

Reading the numbers

Q3 FY2026 comparable store sales growth, 7.9% globally. Comparable store sales, or “comps,” measure revenue only at locations open at least a year, so they strip out the noise of openings and closures. A 7.9% comp means existing Starbucks locations collectively served more customers, or charged more per visit, or both. Here: it was both, with transactions up 4.2% and average ticket up 3.5%. Think of a coffee shop that served 100 customers last July and now serves 104, each spending a little more. That’s the signal the market is reading as a turnaround confirmed.

BullScope TerminalStarbucks was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

FY2025 net margin, 5.0%. The net margin is what’s left of each dollar of sales after every cost, including taxes and interest, is paid. At 5%, Starbucks kept five cents of every dollar it collected last fiscal year. That’s roughly half what it kept in FY2021, when the margin was 14.5%. The gap reflects the real cost of the turnaround year. A saver looking at this number should note that the Q3 2026 non-GAAP margin of 14.4% is a quarterly figure that excludes restructuring charges, so the two numbers are not directly comparable on the same basis.

P/E of 65.5 versus a decade median of 27.3. The price-to-earnings ratio is the price tag the market puts on each dollar of profit. At 65.5, investors are paying more than twice the historical norm for each dollar Starbucks earns today. A decade median of 27.3 means that for most of the past ten years, the market valued a dollar of Starbucks profit at about $27. Today it values that same dollar at $65. The gap is the embedded optimism this audit is testing: it requires not just that the recovery continues, but that it accelerates well beyond what the most recent annual filing shows.

Sources

  • Starbucks 10-Q, quarter ended June 28, 2026 (SEC EDGAR)
  • Starbucks 10-K, fiscal year ended September 28, 2025 (SEC EDGAR)
  • Starbucks 10-K, fiscal year ended September 29, 2024 (SEC EDGAR)
  • Starbucks Q3 FY2026 financial release, July 29, 2026
  • Starbucks Q3 2026 earnings call transcript, The Motley Fool, August 7, 2026
  • Washington Times, July 29, 2026
  • Investing.com, Starbucks Q3 FY2024 earnings report
  • Labor Notes, April 2026
  • Renascence, August 16, 2026
  • Public.com analyst price targets, August 2026
  • Simply Wall St, post-Q3 valuation analysis
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Starbucks’ filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Amgen: The Stock Is Priced for a Future the Filings Haven’t Promised Yet

by Moe Alsumidaie, MBA, MSF
September 8, 2026
0

For most of the past decade, Amgen was a reliable but slow-moving machine: a biotech giant that grew revenues at roughly the pace of the broader economy, collected...

Read moreDetails

A 95% Gross Margin and a P/S Below Its Own Median: PTC Therapeutics’ Profitability Flip Is Real, and the Valuation Gap Raises Questions

by Moe Alsumidaie, MBA, MSF
September 4, 2026
0

In one breath PTC Therapeutics spent the better part of a decade burning cash on a pipeline that mostly disappointed. Then, in the twelve months through the fiscal...

Read moreDetails

Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

Before anything else Moderna's filed revenue has fallen every year since 2022, and the company is burning through roughly $600 million a quarter. The stock, at $150.81, prices...

Read moreDetails

United Therapeutics: The Stock Is Priced for Stagnation. The Filings Tell a Different Story.

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Two facts about United Therapeutics sit side by side right now and refuse to make peace. The company has grown earnings per share from $11.54 in 2020 to...

Read moreDetails

Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug that Medicare ultimately refused to cover. Today the stock sits near $218,...

Read moreDetails
Next Post

Evidence Sheet: Boeing (BA)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Disney’s Numbers Say One Thing. The Stock Price Says Another.

August 11, 2026

Evidence Sheet: Biogen (BIIB)

September 1, 2026

American Express Is Spending More to Earn More. The Filing Says Both Are Working.

August 13, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.